Holen Sie sich die Stockscreener-App
2.39
6.94%
0.155
Handel nachbörslich:
2.56
0.17
+7.11%
Schlusskurs vom Vortag:
$2.235
Offen:
$2.25
24-Stunden-Volumen:
303.99K
Relative Volume:
0.68
Marktkapitalisierung:
$2.79M
Einnahmen:
$1,000
Nettoeinkommen (Verlust:
$-11.39M
KGV:
-0.0778
EPS:
-30.7182
Netto-Cashflow:
$-7.26M
1W Leistung:
-25.31%
1M Leistung:
-44.55%
6M Leistung:
-55.33%
1J Leistung:
-92.70%
1-Tages-Spanne:
$2.1501
$2.39
1-Wochen-Bereich:
$2.1501
$3.2798
52-Wochen-Spanne:
$2.1501
$71.50
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Firmenname
Ernexa Therapeutics Inc
Sektor
Branche
Telefon
(617) 798-6700
Adresse
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
2.39 | 4.02M | 1,000 | -11.39M | -7.26M | -30.72 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ernexa Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
Ernexa appoints Robert Spiegel to board, targets IND filing By Investing.com - Investing.com Canada
Ernexa Therapeutics Says Board Addition Strengthens Oncology Strategy as ERNA-101 Advances Toward the Clinic - Quiver Quantitative
Ernexa Therapeutics Inc. (ERNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ernexa completes safety studies for ERNA-101 cancer therapy By Investing.com - Investing.com Canada
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND - Yahoo Finance
An ovarian cancer study found Ernexa’s cell therapy combo cleared tumors; 100% of animals survived through follow-up. - Stock Titan
ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits
Ernexa (ERNA) director logs zero insider stake in new ownership report - Stock Titan
Ernexa Therapeutics Warrants (ERNAW) Tick Higher to $0.03 as Trading Range Stays Razor-ThinCounter Trend Trade - siam.in
Eterna Therapeutics appoints independent director Robert J. Spiegel - The Globe and Mail
Ernexa Therapeutics Inc. (ERNA) Q2 2026 Earnings: Narrower-Than-Feared Loss Fails to Lift Shares as Pipeline Costs PersistEBITDA Margin Trends - siam.in
Ernexa Therapeutics Announces Appointment of Robert J. Spiegel to Board of Directors - marketscreener.com
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors - Yahoo Finance
Form 8K Ernexa Therapeutics Inc For: 16 September - Investing.com India
Form 8K Ernexa Therapeutics Inc For: 16 September By Investing.com - Investing.com South Africa
Eterna Therapeutics Updates Investors With New Corporate Materials - TipRanks
Ernexa names Robert J. Spiegel to its board - TradingView
Ernexa Therapeutics Reports Positive Preclinical ERNA-201 Data, Prioritizes ERNA-101 Oncology Program Toward IND Filing - Quiver Quantitative
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing - GlobeNewswire
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Price to earnings forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Enterprise value to EBIT forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Enterprise value to revenue forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Should I Buy ERNA? ERNA 2026 AnalysisIntellectia AI™ - Intellectia AI
Director takes 2026 cash pay in options at Ernexa (ERNA) - Stock Titan
Ernexa Therapeutics (ERNA) director granted options in place of cash fees - Stock Titan
Ernexa Therapeutics (ERNA) grants director 5,944-share option - Stock Titan
Ernexa Therapeutics Inc. (ERNA) grants CEO 118,848 options expiring 2036 - Stock Titan
Ernexa (NASDAQ: ERNA) pays director with $4.57 stock options - Stock Titan
Eterna Therapeutics Inc (NASDAQ: ERNA) Share Price, ERNA Stock News, ERNA Share Price & Updates - Kalkine
Ernexa Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Ernexa (NASDAQ: ERNA) director’s warrant set to lapse after Phase 1 data - Stock Titan
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - Yahoo Finance
Ernexa (ERNA) Earnings Reading: Reported EPS Misses Expectations at the Close; Closing Move: The Market Price Advances 3.60%Free Cash Flow Trends - vinanet.vn
Ernexa (ERNA) Quarterly Results: Reported EPS Misses Expectations in the Current Update; Post-Report: The Share Price Adds 4.68% on the DayEBITDA Analysis - vinanet.vn
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - qz.com
Ernexa Therapeutics Warrants (ERNAW) Hold at $0.05 as Price Action Remains FlatAccumulation Line - vinanet.vn
Ernexa Therapeutics (ERNA) Slips 2.2% to $4.17, Testing Key Support Amid Biotech PullbackCatalyst Driven Stocks - vinanet.vn
Ernexa Therapeutics (ERNA) Slips 0.7% to $4.27, Holds Above Key Support at $4.06Regression Channel - vinanet.vn
Ernexa Therapeutics Warrants (ERNAW) Surge 20% to $0.06 as Speculative Interest BuildsFibonacci Extension - vinanet.vn
Ernexa appoints David Polinsky to board ahead of IND filing By Investing.com - Investing.com Nigeria
Ernexa appoints David Polinsky to board ahead of IND filing - Investing.com
Ernexa Therapeutics Strengthens Board with Veteran Biotech - GlobeNewswire
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage - The Manila Times
Ernexa Therapeutics Inc expected to post a loss of $3.84 a shareEarnings Preview - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) details $9.5M loss and cash strategy - Stock Titan
Tranche Update on Ernexa Therapeutics Inc.'s Equity Buyback Plan announced on November 25, 2024. - marketscreener.com
Price to sales forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to earnings forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Enterprise value to EBIT forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Finanzdaten der Ernexa Therapeutics Inc-Aktie (ERNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):